Novo Nordisk has secured a significant regulatory victory, following the United States Food and Drug Administration’s approval of its new weight loss pill containing semaglutide. The decision delivers the Danish
All posts tagged in novo-nordisk
13Articles
Danish pharmaceutical giant Novo Nordisk has revised its profit forecasts downwards for the fourth time this year as competition in the slimming and diabetes treatments market continues to grow. The
Two of the world’s largest pharmaceutical conglomerates have become embroiled in an escalating takeover battle for Metsera, an emerging biotech on the verge of breakthroughs in weight-loss drug innovation. Novo
The powerful Novo Nordisk Foundation, the largest shareholder in pharmaceutical giant Novo Nordisk, has executed a dramatic boardroom takeover after a sharp disagreement about the company’s strategic direction. The move,
Novo Nordisk, the Danish pharmaceutical giant best known for developing the weight-loss injection Wegovy, has announced a landmark deal to acquire US-listed biotech Akero Therapeutics for up to $5.2 billion.
Shares in Novo Nordisk climbed over five per cent on the Copenhagen exchange after the Danish pharmaceuticals firm received crucial approval from the United States Food and Drug Administration for
Novo Nordisk, the Danish pharmaceutical titan known for its diabetes and weight loss treatments Ozempic and Wegovy, now faces a period of significant turbulence. The company has issued a stark
Denmark’s Novo Nordisk has adjusted its annual revenue and profit forecasts downward following weaker-than-expected sales of its weight-loss drug Wegovy in the United States. The company, which became Europe’s most
Danish pharmaceutical giant Novo Nordisk has projected reduced growth for 2025 amidst mounting competition in the weight-loss drugs market from American rivals. The company, renowned for its obesity treatments Ozempic
Danish pharmaceutical giant Novo Nordisk, Europe’s most valuable listed company, has received a stern reprimand from the Prescription Medicines Code of Practice Authority (PMCPA) for systematically failing to disclose healthcare
Novo Nordisk, the Danish pharmaceutical powerhouse, has invested hundreds of thousands of pounds in sponsorship deals with major UK pharmacy chains, including Boots and Lloyds, to enhance sales of its
Danish pharmaceutical giant Novo Nordisk witnessed a staggering $100 billion erosion in market value following disappointing results from its latest obesity drug trial. The company’s shares experienced their most significant
Danish pharmaceutical giant Novo Nordisk has reported exceptional third-quarter results, driven by remarkable sales of its weight-loss treatment Wegovy. The anti-obesity medication generated sales of 17.3 billion Danish krone (£1.96
